An RNA-modifying enzyme drives egg-follicle loss by blocking mitophagy — and blocking it protected follicles, in animal and cell studies

Edited by Samael A. Tejada, Founder & Editor-in-Chief

Quality control is becoming the recurring plot of mitochondrial medicine: here, a single RNA-modifying enzyme throttles the disposal of damaged mitochondria in the cells that nurse an egg, and the follicle pays for the backlog. It is an elegant mechanism with a drug-shaped handle — and it is, today, a mouse-and-culture result, several hard steps from a fertility clinic.

What is the NAT10–ac4C–Tnc chain the paper describes?

NAT10 is an enzyme that installs a chemical modification called ac4C on RNA. The team showed it modifies the messenger RNA encoding Tnc (tenascin C), increasing that message's stability. The consequence runs downhill to mitochondria: the pathway's completion degrades the conditions for Parkin-mediated mitophagy — the tagged disposal route for damaged mitochondria — so defective organelles accumulate, oxidative stress in granulosa cells rises, and follicular atresia progresses. In one sentence: an RNA mark stabilizes a message whose protein product helps switch off mitochondrial housekeeping in the egg's support cells.

What did blocking NAT10 do in the experiments?

The NAT10 inhibitor Remodelin was the test of causality. In cultured granulosa cells, Remodelin promoted mitophagy and inhibited oxidative stress — the two effects the mechanism predicts if NAT10 is genuinely driving them. In vivo, the compound hindered follicular atresia and ameliorated the impaired reproductive efficiency caused by granulosa-cell oxidative stress, acting through the NAT10–ac4C–Tnc pathway. A mechanism that predicts the effect of its own inhibitor, in cells and in animals, is considerably stronger than a correlation — which is why this paper earns attention despite its early stage.

What stands between this and a fertility treatment?

Almost everything clinical. The paper is an accepted manuscript ahead of the final version of record; the in-vivo work is in animal models of oxidative-stress-driven follicle loss, which is one cause among many of human infertility and subfertility. NAT10 modifies many RNAs beyond Tnc, so systemic inhibition raises specificity and safety questions a follicle study cannot answer — dosing, delivery to the ovary, effects on developing eggs themselves, and long-term outcomes all remain open. The realistic near-term value is a target and a pathway: researchers can now ask whether NAT10 activity marks human follicles at risk, before anyone should talk about treating them.

Where the evidence stands

• Established: Follicular atresia eliminates most ovarian follicles before ovulation; granulosa-cell oxidative stress contributes to it; and Parkin-mediated mitophagy is a principal route for clearing damaged mitochondria.
• Preliminary: In cell and animal studies (Cell Death Discovery, Oct 25, 2026; DOI 10.1038/s41420-026-03423-1), NAT10-driven ac4C modification of Tnc mRNA suppressed Parkin-mediated mitophagy and raised granulosa-cell oxidative stress, and the NAT10 inhibitor Remodelin restored mitophagy in vitro and reduced follicular atresia in vivo.
• Absent: Human data of any kind, safety or specificity data for NAT10 inhibition in people, and any clinical fertility outcome.